Form 4: FMR LLC Plans Future Sale of Structure Therapeutics Shares Under 10b5-1 Plan

FMR LLC, a significant 10% owner of Structure Therapeutics Inc., has disclosed a pre-planned sale of 26,310 American Depositary Shares scheduled for July 30, 2025, under a Rule 10b5-1 trading plan.

Summary

• FMR LLC, identified as a 10% owner of Structure Therapeutics Inc. (GPCR), has filed a Form 4.
• The filing indicates a planned disposition (sale) of 26,310 American Depositary Shares (ADS) on July 30, 2025.
• Each American Depositary Share represents three Ordinary Shares of Structure Therapeutics Inc.
• The sale price for the American Depositary Shares is reported as $17.87 per share.
• This transaction is being made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this planned transaction, FMR LLC and its related entities will beneficially own 1,515,558 American Depositary Shares indirectly.
• Indirect beneficial ownership includes 45,120 Ordinary Shares held by F-Prime Capital Partners Life Sciences Advisors Fund VI LP and 530,814 Ordinary Shares held by F-Prime Capital Partners Life Sciences Fund VI LP.

Sentiment

Score: 3

Explanation: The planned sale by a significant 10% owner is generally a negative signal. However, the transaction is pre-planned under Rule 10b5-1, which suggests a systematic approach rather than an immediate reaction to new adverse information, slightly mitigating the negative sentiment.

Negatives

• A planned sale of shares by a 10% owner, FMR LLC, could be perceived as a negative signal regarding the insider's long-term outlook on the company's stock performance.

Future Outlook

The filing details a specific future transaction (a planned sale of shares) but does not provide broader forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

This filing is an insider transaction report, which reflects the investment decisions of a significant shareholder rather than broader industry trends. While not directly indicative of industry-wide shifts, such transactions can influence investor sentiment within the specific sector if interpreted as a signal about the company's future prospects relative to its peers.

Related Party Transactions

• F-Prime Capital Partners Life Sciences Advisors Fund VI LP and F-Prime Capital Partners Life Sciences Fund VI LP, which hold indirect beneficial ownership, are related parties to FMR LLC. Impresa Management LLC, which manages F-Prime Capital Partners Life Sciences Advisors Fund VI LP, is owned by shareholders and employees of FMR LLC, including certain members of the Johnson family.

Stakeholder Impact

• Shareholders may view the planned sale by a significant owner as a negative indicator, potentially impacting investor confidence and the company's stock price.

Next Steps

• The planned sale of 26,310 American Depositary Shares is scheduled to occur on July 30, 2025.

Key Dates

Recommendation

The planned sale by FMR LLC, a 10% owner, while a negative signal, is part of a pre-arranged Rule 10b5-1 plan. This suggests a systematic approach to share disposition rather than an immediate reaction to new negative information. Investors should monitor future filings and company performance, but this single, pre-planned transaction does not immediately warrant a 'sell' recommendation. A 'hold' stance allows for observation of subsequent developments.

Keywords

Structure Therapeutics, GPCR, FMR LLC, Insider Sale, Form 4, Beneficial Ownership, American Depositary Shares, Rule 10b5-1